Product Launch:
Phadia launches EliA Cardiolipin IgA and EliA ß2-Glycoprotein I IgA

Phadia is pleased to announce the availability of two new fully automated tests to help in more specific diagnosis of the Antiphospholipid Syndrome (APS).

The new assays complement the already existing EliA APS tests (Cardiolipin IgG, IgM and EliA ß2-Glycoprotein I IgG, IgM) and will assist to assure the diagnosis of APS.

The new parameters are in particular helpful in confirming the tentative diagnosis APS, especially in conjunction with other serological data and in questionable cases. In addition, patients may be found negative in IgG or IgM, but exclusively positive in IgA.

Both tests perform highly consistent and can be run on our Phadia Laboratory Systems ‘Phadia 100’, ‘Phadia 250’ and ‘Phadia 2500’. The new tests are meaningful add-on tests to the Phadia APS testing und due to the established and comfortable Phadia instruments easy to add to the laboratory autoimmune testing panel. 

For further information click here (pdf) .




As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.